Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig

mediaphotos

• Kamada (NASDAQ:KMDA) said it secured a $11.4M agreement to supply chickenpox preventive antibody Varizig to an undisclosed international organization operating in Latin America.
• Varizig contains antibodies specific for the Varicella zoster virus, and is indicated for post-exposure prevention of varicella (chickenpox) in high-risk patient groups. Varizig is intended to reduce the severity of chickenpox infections in these patients, which include immunocompromised children, newborns, and pregnant women, according to the company's July 6 press release.
• Kamada said Varizig is made by Emergent BioSolutions (NYSE:EBS) at a facility in Winnipeg, Manitoba, Canada, under a manufacturing service agreement.
• Kamada added that the supply of the product is expected to occur from Q4 2022 through H1 2023.
• "We are extremely pleased with this significant supply agreement, which strongly validates our ability to grow the sales of our newly acquired portfolio of four FDA-approved plasma-derived specialty IgGs in the international markets," said Kamada's CEO Amir London.
• KMDA +2.64% to $4.67 premarket July 6